Silexion Therapeutics raised roughly $2.5 million by selling 2,028,619 ordinary shares, 1,817,542 pre‑funded warrants and 3,846,161 ordinary warrants at $0.65 per share. The Capital will support the SIL204 clinical trial and provide Liquidity for general corporate needs, extending the company’s financial runway.

Key Highlights

  • Offered 2,028,619 ordinary shares at $0.65 per share, generating about $2.5 million gross proceeds.
  • Issued 1,817,542 pre‑funded warrants, exercisable at $0.0001 per share, and 3,846,161 ordinary warrants exercisable at $0.65 per share.
  • Converted a $750,001 sponsor note into 1,153,848 shares, reducing note balance to $206,462 and boosting shareholders’ Equity to roughly $3.2 million.

The transaction generated gross proceeds of approximately $2.5 million, reflecting the total cash inflow before any deductions. After accounting for Underwriting commissions, legal fees, filing expenses, and other customary costs, the net proceeds settled at roughly $2.1 million. This differential illustrates the typical expense ratio associated with capital raises of this scale, where a modest portion of the cash raised is consumed by transaction costs.

For an investor, the net figure is the amount effectively available to the company for operational deployment, while the gross amount provides a benchmark for assessing the overall market appetite. The retention of $2.1 million underscores the firm’s capacity to fund near‑term initiatives without immediate equity dilution beyond the offering itself. The gap between gross and net proceeds highlights the importance of evaluating fee structures when weighing participation in similar offerings.

Ultimately, the net proceeds serve as the primary financial lever driving the company’s strategic objectives, while the gross proceeds offer a broader perspective on market valuation at the time of issuance.

Offering Structure and Pricing

The offering was structured as a three‑component package that blended direct equity with contingent equity instruments, thereby catering to varied investor risk tolerances. The first component involved the issuance of 2,028,619 ordinary shares, each carrying a nominal Par Value of $0.135 and sold at a price of $0.65 per share, establishing a clear price floor for new investors. The second component, though not detailed here, typically includes a Debt or convertible element that complements the equity features, further diversifying the capital mix.

The third component consisted of 3,846,161 ordinary warrants, also priced at $0.65 per share, which are immediately exercisable and carry a five‑year expiration horizon, granting holders the right to acquire additional shares at a fixed price within that window. To mitigate concentration risk, the agreement caps any Warrant holder’s beneficial ownership at 4.99 % of the post‑exercise ordinary share count, with an elected ceiling of 9.99 %, ensuring a balanced distribution of voting power. This layered architecture delivers flexible entry points for investors while preserving the company’s ability to control its equity composition and avoid excessive dilution.

Placement Agent Fees and Warrants

The Placement agent warrants are priced at an exercise level of $0.8125 per share, representing a 125 % premium over the public offering price of $0.65 per share. By setting the exercise price above the initial offering level, the arrangement aligns the agent’s financial interests with the company’s goal of maximizing capital raised, as the agent only benefits if the share price appreciates beyond the initial issuance price. This structure incentivizes the placement agent to target sophisticated investors and to support market performance that pushes the stock price higher, thereby enhancing overall transaction efficiency.

For shareholders, the premium exercise price serves as a protective buffer against immediate dilution, because the warrants will only be exercised if the market perceives sufficient value. Consequently, the agent’s potential upside is directly tied to the company’s successful execution of its growth plans, creating a symbiotic relationship where both parties benefit from a rising equity price.

Sponsor Note Conversion and Equity Impact

The conversion of the sponsor note trimmed the outstanding note balance to $206,462, effectively reducing the company’s debt burden and converting that Liability into equity. When this conversion is combined with proceeds from at‑the‑market sales, the recent offering, and warrant exercises, the resulting shareholders’ equity is estimated at approximately $3.2 million as of June 30, 2026. This infusion of equity, coupled with the debt reduction, strengthens the Balance Sheet by improving leverage ratios and expanding the capital base available for strategic initiatives.

Enhanced financial flexibility supports the ongoing Research and Development pipeline, allowing the firm to fund critical milestones without resorting to additional high‑cost financing. For investors, the bolstered equity position signals a lower risk profile and a potentially more resilient valuation foundation. The net effect is a corporate financial structure better equipped to weather market fluctuations while pursuing its growth objectives.

Forward Catalyst and Investor Considerations

The ordinary warrants issued in the offering are exercisable until the five‑year anniversary of their issuance, i.e. August 13, 2031, providing investors with a long‑term upside potential tied to the company’s future share price. The combined capital from the offering and the note conversion is slated for the SIL204 clinical trial and broader corporate purposes, meaning that progress on that trial will be a key driver of subsequent valuation movements. As the company advances these initiatives, the performance of the ordinary warrants and the dilution from any further equity raises will be focal points for shareholders monitoring the firm’s Capital Structure and strategic execution.